- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07172659
- Original retssag
Effektivitet og sikkerhedsundersøgelse af dovramilast hos mennesker med spedalsk type 2 -reaktion
En 12-ugers, åben mærket, randomiseret, standard for plejekontrolleret, dosisranging af sikkerhed og effektivitetsundersøgelse af dovramilast hos mennesker med moderat til svær akut eller tilbagevendende spedalskhed Type 2-reaktion
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Abomey-Calavi, Benin
- Ikke rekrutterer endnu
- Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
-
-
-
-
-
Divo, Côte d’Ivoire
- Ikke rekrutterer endnu
- Chr de Divo
-
-
-
-
-
Manila, Filippinerne
- Rekruttering
- Philippine General Hospital, University of the Philippines, Manila
-
Kontakt:
- Dofitas
- Telefonnummer: 63285548400
- E-mail: bldofitas@up.edu.ph
-
-
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Rekruttering
- Harborview Medical Center, University of Washington
-
Kontakt:
- Dr Jason Simmons, MD, PhD
- Telefonnummer: 206-744-5463
- E-mail: jasonds@uw.edu
-
-
-
-
-
Yogyakarta, Indonesien
- Rekruttering
- Universitas Gadjah Mada
-
Kontakt:
- Shinta Trilaksmi Dewi, MD, PhD
- Telefonnummer: +6282137381045
- E-mail: shinta.trilaksmi.d@ugm.ac.id
-
-
-
-
-
Tôlanaro, Madagaskar
- Rekruttering
- Programme national lutte contre la lèpre
-
Kontakt:
- Andrinamira Randrianantoandro, MD
- Telefonnummer: +261 340600115
- E-mail: andriamiradomoina@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Aged 18 years of age or older.
-
Provision of written informed consent.
-
Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.
-
Leprosy type 2 reaction meeting the following criteria:
-
Either:
i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).
-
Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).
-
An ENLIST score of at least 9.
-
-
If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.
-
If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.
Exclusion Criteria:
-
Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.
-
Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.
-
Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).
-
Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).
-
Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.
-
Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.
-
Active systemic fungal infection requiring or undergoing treatment.
-
Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
-
Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.
-
Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.
-
Pregnant women or breastfeeding mothers.
-
Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.
-
Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.
-
Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
-
Current diagnosis of depression, and/or history of suicide ideation
-
History of or presence of cardiac disease, including:
- Clinically significant abnormal electrocardiogram
- QTcF > 450 msec
-
Receipt of a vaccination within 7 days of Baseline.
-
Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.
-
Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.
-
Unable to, or significant difficulty with, swallowing tablets/capsules.
-
Anemia requiring transfusion.
-
History of or current pancreatitis.
-
Known or suspected cirrhosis of the liver.
-
The following laboratory abnormalities:
- White blood cells (WBC) < 2.5 x 10^9/ L.
- Neutrophils (granulocytes) < 1.0 x 10^9/L.
- Platelets < 80 x 10^9/L.
- Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
- Albumin < 30 mg/dL.
- Bilirubin > 2 mg/dL
- Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
- Lipase ≥ 1.6 times the upper limit
-
Previous participation in this study
-
Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments
-
Enrolled in another leprosy type 2 reaction treatment study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dovramilast 100 mg
|
Dovramilast |
|
Eksperimentel: Dovramilast 150 mg
|
Dovramilast |
|
Aktiv komparator: Standard of care
Prednisolone (or thalidomide US sites only) |
Standard of care Standard of care (US only) |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
Tidsramme: 12 weeks
|
The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue. Rescue is defined as:
|
12 weeks
|
|
Incidence and severity of adverse events
Tidsramme: 12 weeks
|
The incidence and severity of adverse events, changes in vital signs and blood dyscrasias |
12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ændring fra baseline -enlist (erythema nodosum leprosum international undersøgelse) Alvorlighedsskala score
Tidsramme: Ved hvert postbaseline -tidspunkt
|
Ved hvert postbaseline -tidspunkt
|
|
|
Ændringer i neuropati fra baseline -kvalitet
Tidsramme: 12 uger
|
12 uger
|
|
|
Andel af personer, der kræver redningsmedicin og tid til at indlede redningsmedicin
Tidsramme: 12 uger
|
12 uger
|
|
|
Samlet behandlingsmængde for administreret af spedalskhed Type 2
Tidsramme: 12 uger
|
12 uger
|
|
|
Resolution of fever to ≤ Grade 1
Tidsramme: 12 weeks
|
Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater. |
12 weeks
|
|
Skin lesion count changes
Tidsramme: 12 weeks
|
• Change from Baseline in skin lesion count up to and including Week 12. |
12 weeks
|
|
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
Tidsramme: from baseline to Week 12
|
|
from baseline to Week 12
|
|
Time to resolution
Tidsramme: 12 weeks
|
For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline |
12 weeks
|
|
Recurrences
Tidsramme: 48 weeks
|
Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment. |
48 weeks
|
|
Exposure metrics of dovramilast
Tidsramme: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Exposure metrics of the dovramilast metabolite M15
Tidsramme: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Skin lesion count changes
Tidsramme: 12 weeks
|
• Proportion of Responders at each post-Baseline timepoint. |
12 weeks
|
|
Skin lesion count changes
Tidsramme: 12 weeks
|
Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12. |
12 weeks
|
|
Exposure metrics of dovramilast
Tidsramme: 48 weeks
|
Including AUC, Cmax, and Tmax. |
48 weeks
|
|
Exposure metrics of dovramilast
Tidsramme: 48 weeks
|
Cmax |
48 weeks
|
|
Exposure metrics of dovramilast
Tidsramme: 48 weeks
|
Tmax. |
48 weeks
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsramme: 48 weeks
|
Concentration of inflammatory cytokines |
48 weeks
|
|
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
Tidsramme: 48 weeks
|
Leukocyte infiltration of skin lesions by histology |
48 weeks
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ring
- Carboxylsyrer
- Polycykliske forbindelser
- Piperidiner
- Gravidier
- Graviditet
- Steroider
- SMUSED-RING-forbindelser
- Gravideretrioler
- Phthalimider
- Phthalinsyrer
- Syrer, carbocykliske
- Piperidones
- Isoindoler
- Prednisolon
- Thalidomid
Andre undersøgelses-id-numre
- MDGH-DOV-2001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .